A peptide-based gene carrier that specifically targets fat cells in a mouse model of obesity can deliver a therapeutic gene, which helps reduce body weight, reports a paper published online this week in Nature Materials. Although future studies are needed to test its feasibility and safety in humans, the molecular complex could be used to treat obesity and obesity-induced metabolic syndromes.
Obesity is often a result of over-eating, which results in the storage of energy in fat tissue. Therefore, fat tissue is a target for anti-obesity therapies, but in the case of gene delivery systems, it has not been possible to apply gene therapy to fat cells because the cells are difficult to transfect.
Yong-Hee Kim and colleagues created a gene carrier that comprises a short peptide with a gene sequence for targeting fat cells and the natural amino acid, arginine. They show that this gene carrier can selectively deliver genetic material to mature fat cells by binding to a protein found on the surface of the cells. The authors find that injecting these gene carriers into obese mice results in specific binding of the gene carrier to fat vasculature, followed by internalization and gene expression in the fat cells. The incorporation of a therapeutic gene (composed of a short hairpin RNA for silencing fatty-acid-binding protein-4) results in the formation of an oligopeptide complex. Kim and colleagues found that when they injected this oligopeptide complex into obese mice, it led to metabolic recovery and body-weight reduction greater than 20%.
Ecology: Fast-growing trees die young and could affect carbon storageNature Communications
Epidemiology: US COVID-19 cases may be substantially underestimatedNature Communications
Environment: Atlantic Ocean contains more plastic than previously thoughtNature Communications